Cambridge Nutritional Science (CNSL)

Sector:

Health Care

Index:

FTSE AIM All-Share

4.15p
   
  • Change Today:
      0.050p
  • 52 Week High: 4.24p
  • 52 Week Low: 1.73p
  • Currency: UK Pounds
  • Shares Issued: 237.95m
  • Volume: 495,522
  • Market Cap: £9.87m

Omega upbeat on Covid test consortium developments

By Josh White

Date: Monday 29 Jun 2020

LONDON (ShareCast) - (Sharecast News) - Omega Diagnostics updated the market on an announcement from the UK Rapid Test Consortium (UK-RTC) on Monday, developing a Covid-19 lateral flow antibody test that could be used by people in their homes.
The AIM-traded firm had announced on 9 April that it signed a memorandum of understanding with Abingdon Health, BBI Solutions, CIGA Healthcare, and the University of Oxford, to form the UK-RTC to jointly develop and manufacture a Covid-19 rapid test as part of the government's "five pillar" national testing strategy for the coronavirus pandemic.

Abingdon Health, lead partner of the UK-RTC, had now told consortium members that it has attained design freeze for the Covid-19 rapid test.

The next stage was for Abingdon Health to complete verification, validation, transfer the manufacturing protocols to consortium members, and gain regulatory approval, Omega explained.

It said the transfer of the manufacturing process to itself would enable the firm to undertake its own validation work, to prove equivalent performance, and to demonstrate the test could be manufactured at scale to meet the UK government's demand.

Those activities would begin immediately, the board said, and the company said it expected to complete that work by the end of August.

Initially, it was Omega's plan to produce 100,000 tests per week, scaling up to 200,000 tests per week by the end of September.

Based on demand for its wider Covid-19 test portfolio, Omega said it had the flexibility in the use of its overall manufacturing capacity, so that more could be allocated to the UK-RTC if required.

"This key milestone achievement in such a short timescale is a credit to the hard work put in by the consortium, especially Abingdon Health," said chief executive officer Colin King.

"We can now look forward with greater confidence in bringing this important test to market to support the UK and devolved Governments in their fight against this pandemic."

At 1138 BST, shares in Omega Diagnostics were down 2.48% at 47.98p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

CNSL Market Data

Currency UK Pounds
Share Price 4.15p
Change Today 0.050p
% Change 1.22 %
52 Week High 4.24p
52 Week Low 1.73p
Volume 495,522
Shares Issued 237.95m
Market Cap £9.87m

CNSL Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend
83.32% above the market average83.32% above the market average83.32% above the market average83.32% above the market average83.32% above the market average
83.33% above the sector average83.33% above the sector average83.33% above the sector average83.33% above the sector average83.33% above the sector average
Income Not Available
Growth
45.82% below the market average45.82% below the market average45.82% below the market average45.82% below the market average45.82% below the market average
61.11% below the sector average61.11% below the sector average61.11% below the sector average61.11% below the sector average61.11% below the sector average

CNSL Dividends

No dividends found

Trades for 28-May-2024

Time Volume / Share Price
13:22 94,339 @ 4.24p
11:35 27,512 @ 4.10p
11:08 12,522 @ 4.08p
10:44 71,154 @ 4.20p
10:34 13,432 @ 4.06p

Top of Page